Patient Derived Xenograft Model Market to be substantial growth owing to Increasing need for individualized care is expected to drive market expansion in the near future

Market Highlights

The global patient derived xenograft model market is accounted to register a CAGR of 13.30% during the forecast period and is estimated to reach USD 0.759 Billion by 2032.

The patient-derived xenograft (PDX) model market is witnessing growth as a crucial tool in cancer research and drug development. PDX models, which involve transplanting patient tumor tissue into immunodeficient mice, offer a more accurate representation of human responses to treatments. Their potential to enhance personalized medicine and preclinical studies is driving market demand.

key Players

MRFR recognizes the following companies as the key players in the global patient derived xenograft model market— Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp. and others

Segment Analysis

The global Patient derived xenograft model market has been segmented based tumor type, model type and end-user.

On the basis of tumor type, the market is segmented into lung cancer, pancreatic cancer, prostate cancer, breast cancer and other cancer. The breast cancer segment dominated the market in 2022. The landscape of treatment for specific breast cancer subtypes has evolved as a result of the development of targeted drugs, such as hormone therapy and drugs that target the HER2 gene.  

Based on model type, the global patient derived xenograft model market has been segmented into mice and rats. The mice category generated the most income in 2022. Because they are biologically relevant and have a higher genetic connection to humans than other animals, mice are frequently utilized as hosts for patient tumor tissues.

Based on end-user, the global patient derived xenograft model market has been segmented into pharmaceutical and biopharmaceutical companies, academic & research institutes and CROs & CDMOs. The CROs & CDMOs segment dominated the market in 2022. Contrasting the price of developing and maintaining in-house knowledge with the price of outsourcing PDX model-related research to CROs and CDMOs.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Patient Derived Xenograft Model Market Research Report

Regional Analysis

The global patient derived xenograft model market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Patient derived xenograft model market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Patient derived xenograft model market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Patient derived xenograft model market comprises of Middle East, Africa, and Latin America.

The North America patient derived xenograft model market dominated this market in 2022 (45.80%). North America also has a sizable pharmaceutical industry, which is headquartered mostly in the US. This area of the economy is primarily responsible for the demand for PDX models. Due to the constant need for new treatment options, pharmaceutical companies in North America rely on PDX models for their exceptional ability to faithfully mimic human tumor responses. This promotes collaboration and research relationships with academic institutions, which ultimately broadens the market for PDX models.

Moreover, the second-largest market share belongs to the patient-derived xenograft model market in Europe. The main force behind the spread of the PDX model in Europe is international cooperation. European countries encourage inter-institutional collaboration because it fosters significant information sharing and resource sharing for PDX model research. This cooperative mindset fosters a thriving research environment where ideas are freely shared, hastening the advancement of PDX model technology and applications.

Additionally, the Asia-Pacific patient derived xenograft model market is expected to grow at the fastest CAGR from 2023 to 2032. The Asia-Pacific region's growth in the PDX model market is mostly attributable to the region's thriving biotechnology sector. Nations like China, Japan, and South Korea have made large investments in the production of pharmaceuticals and the study of the biological sciences. PDX models have grown in importance as a result of the advent of biotechnology for preclinical drug testing and cancer research.

Furthermore, the rest of the world's patient derived xenograft model market is divided into the Middle East, Africa, and Latin America. In Latin America, the patient-derived xenograft (PDX) model market is advancing cancer research and drug development. PDX models offer more accurate insights into human responses, aiding personalized medicine efforts and elevating preclinical studies to meet the region's healthcare needs.

Key Findings of the Study

• The global patient derived xenograft model market is expected to reach USD 0.759 Billion by 2032, at a CAGR of 13.30% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. The booming biotechnology industry in the Asia-Pacific region is primarily responsible for the area's rise in the PDX model market.


• Based on model type, the mice segment was attributed to holding the largest market in 2022.


• Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp. and others.